Home » Posts tagged with » respiratory syncytial virus
Pfizer begins phase 3 clinical trials of 20vPnC, RSVpreF, and MenABCWY vaccine candidates

Pfizer begins phase 3 clinical trials of 20vPnC, RSVpreF, and MenABCWY vaccine candidates

US pharma giant Pfizer has initiated four phase 3 clinical trials within its present pipeline of investigational vaccines. The company’s 20vPnC, which is a 20-valent pneumococcal polysaccharide conjugate vaccine candidate, will be evaluated in two phase 3 trials NCT04382326 and NCT04379713. Both the late-stage trials will evaluate a four-dose series in infants starting at the […]

Icosavax, a new vaccine development company, launched in Seattle

Icosavax, a new pharma company, focused on developing vaccines against infectious diseases, has been launched in Seattle, Washington. The vaccine development company is backed by $51 million capital raised through a Series A financing round led by Qiming Venture Partners USA. Other investors in Icosavax are Sanofi Ventures, Adams Street Partners, and NanoDimension, alongside continuing […]

Continue reading …